Floatz logo

Recombinant Vesicular Stomatitis Virus-Expressing Human Interferon Beta And Sodium-Iodide Symporter

Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

Mayo ClinicvaccinePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
cc-5013
National Cancer Institute (NCI)
Phase 2BBB
Nivolumab
Mayo Clinic
Phase 2B
Parsaclisib
Walter Hanel
Phase 1CC
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER
Mayo Clinic
Phase 1CC
FLUDEOXYGLUCOSE
Mayo Clinic
Phase 1CC

View all 12 →

Same molecule, other indications

Recombinant Vesicular Stomatitis Virus-Expressing Human Interferon Beta And Sodium-Iodide Symporter is also rated in:

Advanced Clear Cell Renal Cell CarcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
Stage III Renal Cell Cancer AJCC v8Dormant
CCC
Indicative ·
53 / 100
View asset →
Recurrent Adult Acute Myeloid LeukemiaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →